BioSpace News Archive

Olympus Corporation, a global medical technology company committed to making people’s lives healthier, safer and more fulfilling, announced today the market launch of its next-generation EVIS X1™ endoscopy system, which will be on display and demonstrated Oct. 22-24 during the American College of Gastroenterology (ACG) annual meeting in Vancouver, Canada.

Adial Pharmaceuticals, Inc. announces it has been awarded a key patent combining the use of the Company’s proprietary genetic diagnostic to detect select genotypes for genetically target treatment of alcohol use disorder and opioid use disorder with the Company’s lead investigational new drug product AD04.

Digital health startup CARI Health was awarded an SBIR Fast Track grant from the National Institute on Drug Abuse, an agency of the National Institutes of Health, to help it bring the world’s first wearable medication monitor to market.

Approximately 2.3 million Americans live with bipolar disorder who are impacted by dramatic shifts in mood, energy and activity levels.

Median Technologies, whose board of Directors approved the consolidated IFRS financial statements for the first half of 2023 on October 18, 2023, announces its half-year results as well as business indicators for Q3 2023.

Johnson & Johnson announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2023 of $1.19 per share on the company’s common stock.

AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced the topline results from its Phase 2 clinical trial of ABP-450 (prabotulinumtoxinA) for the preventive treatment of episodic migraine.

Terns Pharmaceuticals, Inc. announced that members of management will be participating in the following upcoming investor conferences.

Arcutis Biotherapeutics, Inc. announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2023 financial results prior to the market open on Friday, November 3, 2023.